12 Month Price Forecast For CMRX
Distance to CMRX Price Forecasts
CMRX Price Momentum
🤔 Considering Chimerix (CMRX)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: December 13, 2024 10:08 AM UTC
CMRX Analyst Ratings & Price Targets
Based on our analysis of 5 Wall Street analysts, CMRX has a consensus that is bullish. The median price target is $8.00, with forecasts ranging from $6.00 to $11.00. Currently, there are 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With CMRX currently trading at $2.94, the median price forecast suggests a 172.1% upside. The most optimistic forecast comes from Edward White at HC Wainwright & Co., projecting a 274.1% upside, while David Nierengarten at Wedbush provides the most conservative target, suggesting a 104.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CMRX Analyst Consensus
CMRX Price Target Range
Latest CMRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CMRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 11, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $11.00 |
| Nov 18, 2024 | Wedbush | David Nierengarten | Outperform | Reiterates | $6.00 |
| Nov 11, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $11.00 |
| Aug 14, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $11.00 |
| Mar 1, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $11.00 |
| Aug 17, 2023 | Wedbush | David Nierengarten | Outperform | Reiterates | $6.00 |
| Aug 16, 2023 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $11.00 |
| Aug 4, 2023 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $11.00 |
| May 23, 2023 | Baird | Joel Beatty | Outperform | Initiates | $7.00 |
| May 5, 2023 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $11.00 |
| Mar 3, 2023 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $11.00 |
| Sep 7, 2022 | Capital One | Naureen Quibria | Overweight | Initiates | $7.00 |
| May 17, 2022 | HC Wainwright & Co. | Edward White | Buy | Maintains | $11.00 |
| Dec 22, 2021 | HC Wainwright & Co. | Edward White | Buy | Maintains | $24.00 |
| Nov 22, 2021 | HC Wainwright & Co. | Edward White | Buy | Maintains | $21.00 |
| Jun 7, 2021 | HC Wainwright & Co. | Edward White | Buy | Maintains | $19.00 |
| May 6, 2021 | HC Wainwright & Co. | Buy | Maintains | $18.00 | |
| Apr 29, 2021 | Maxim Group | Buy | Initiates | $0.00 | |
| Mar 31, 2021 | Wedbush | Outperform | Initiates | $0.00 | |
| Mar 31, 2021 | Jefferies | Buy | Initiates | $0.00 |
Chimerix Inc (CMRX) Financial Data
Chimerix Inc has a market capitalization of $268.01M with a P/E ratio of 0.5x. The company generates $159,000 in trailing twelve-month revenue with a 100.0% profit margin.
Revenue growth is +136.4% quarter-over-quarter, while maintaining an operating margin of -95,357.7% and return on equity of -48.6%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Chimerix Inc (CMRX) Company Overview
About Chimerix Inc
Develops medicines for deadly diseases.
Chimerix, Inc. operates as a biopharmaceutical company focusing on the development of innovative therapeutics aimed at improving patient outcomes in deadly diseases. The company primarily generates revenue through partnerships, licensing agreements, and potential future sales of its drug candidates, which are currently in various phases of clinical trials.
Chimerix's pipeline includes ONC201 for H3 K27M-mutant diffuse glioma, ONC206 for primary central nervous system tumors, and CMX521 for SARS-CoV-2. The company has a licensing agreement with SymBio Pharmaceuticals for TEMBEXA, expanding its reach in treating diseases beyond orthopoxviruses. Founded in 2000 and based in Durham, North Carolina, Chimerix aims to address significant unmet medical needs.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
72
CEO
Mr. Michael T. Andriole M.B.A.
Country
United States
IPO Year
2013
Website
www.chimerix.comChimerix Inc (CMRX) Latest News & Analysis
Chimerix: Big News, Big Moves, So Maybe Now's The Time To Buy
2 days agoChimerix's dordaviprone shows potential for H3 K27M-positive glioma, with possible FDA approval by Q3 2025. CMRX has 6–7 quarters of cash runway, but faces dilution risks.
Chimerix's promising drug for a rare glioma could lead to FDA approval and a commercial launch, impacting stock performance. Cash runway supports development, but dilution risks must be monitored.
Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End
4 days agoChimerix plans to submit a New Drug Application for dordaviprone to treat recurrent H3 K27M-mutant diffuse glioma by year-end 2024, with potential FDA approval in Q3 2025.
The potential FDA approval for dordaviprone could significantly impact Chimerix's stock value, signaling progress in addressing a critical medical need and attracting investor interest.
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
7 days agoChimerix (NASDAQ:CMRX) granted inducement awards of non-statutory stock options for 385,000 shares to three new employees on December 2, 2024, per Nasdaq rules.
The granting of stock options to new employees can signal company growth and confidence in future performance, potentially affecting stock value and investor sentiment.
Chimerix, Inc. (CMRX) Q3 2024 Earnings Call Transcript
1 month agoChimerix, Inc. (NASDAQ:CMRX) will hold its Q3 2024 Earnings Call on November 7, 2024, at 8:30 AM ET, featuring key executives including the CEO and CFO.
Chimerix's Q3 earnings call reveals financial performance and strategic insights, impacting stock valuation, investor sentiment, and market positioning in the biotech sector.
Chimerix (CMRX) Reports Q3 Loss, Lags Revenue Estimates
1 month agoChimerix (CMRX) reported a quarterly loss of $0.26 per share, slightly worse than the estimated loss of $0.24, and improved from a loss of $0.27 per share a year prior.
Chimerix's larger-than-expected quarterly loss signals ongoing financial challenges, potentially impacting investor confidence and stock performance.
Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024
1 month agoChimerix (NASDAQ: CMRX) will host a conference call on November 7, 2024, at 8:30 a.m. ET to discuss Q3 2024 financial results and provide a business overview.
Chimerix's upcoming financial results call may impact stock performance, revealing insights into its growth prospects and operational status, critical for assessing investment potential.
Frequently Asked Questions About CMRX Stock
What is Chimerix Inc's (CMRX) stock forecast for 2025?
Based on our analysis of 5 Wall Street analysts, Chimerix Inc (CMRX) has a median price target of $8.00. The highest price target is $11.00 and the lowest is $6.00.
Is CMRX stock a good investment in 2025?
According to current analyst ratings, CMRX has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.94. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for CMRX stock?
Wall Street analysts predict CMRX stock could reach $8.00 in the next 12 months. This represents a 172.1% increase from the current price of $2.94. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Chimerix Inc's business model?
Chimerix, Inc. operates as a biopharmaceutical company focusing on the development of innovative therapeutics aimed at improving patient outcomes in deadly diseases. The company primarily generates revenue through partnerships, licensing agreements, and potential future sales of its drug candidates, which are currently in various phases of clinical trials.
What is the highest forecasted price for CMRX Chimerix Inc?
The highest price target for CMRX is $11.00 from Edward White at HC Wainwright & Co., which represents a 274.1% increase from the current price of $2.94.
What is the lowest forecasted price for CMRX Chimerix Inc?
The lowest price target for CMRX is $6.00 from David Nierengarten at Wedbush, which represents a 104.1% increase from the current price of $2.94.
What is the overall CMRX consensus from analysts for Chimerix Inc?
The overall analyst consensus for CMRX is bullish. Out of 5 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $8.00.
How accurate are CMRX stock price projections?
Stock price projections, including those for Chimerix Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
